Researchers track Long-Term risks of cancer immunotherapy
NCT ID NCT06887348
First seen Jan 12, 2026 · Last updated Apr 24, 2026 · Updated 17 times
Summary
This study watches 50 people who already received Replimune's cancer immunotherapy to see if any side effects show up later. Participants are followed for 5 years with no new treatment. The goal is to make sure the therapy is safe over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tasman Oncology Research
RECRUITINGSouthport, Queensland, 4215, Australia
Contact
-
UC San Diego Moores Cancer Center
RECRUITINGLa Jolla, California, 92093-0698, United States
Contact
Conditions
Explore the condition pages connected to this study.